NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)

NNBP 0.0001000

0.0%

Mar 7 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: da_cheif™	9/12/2007 10:02:16 AM
	of 106

Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States "Test Available 4th Quarter 2007" TAMPA, Fla., Sep 12, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S. The tests can detect CNP antigens and antibodies. Analysis will be performed at AHA's main laboratory in Miramar. Nanobac's laboratory in Finland will continue to service the world market after having performed thousands of such tests worldwide since the year 2000. "This is the continuation of our new business strategy that was announced on our investor conference call three weeks ago," commented Alex Edwards Director Nanobac Pharmaceuticals. "Making our diagnostic test for CNPs available under IUO conditions will help meet the growing demand from patients and physicians throughout the country. This is the first step toward acceptance of our NB2 test as a valuable health evaluation tool and potentially a standard of care in this country." Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next